Six million donkeys slaughtered for Chinese medicine: Charity
Almost six million donkeys are slaughtered annually for Chinese medicine, with severe knock-on effects for African villagers who rely on the animals, a UK-based charity said on Thursday.
It is driven by an increase in China's production of ejiao — a product marketed as a health supplement that uses collagen from donkey skins — which is a $6.8-billion industry, according to China-based research firm Qianzhan.
China, whose donkey population has plummeted from 11 million in 1992 to 1.5 million in 2023, has turned to Africa to meet its demand.
With donkey populations falling, the African Union issued a 15-year moratorium on donkey slaughter last year.
UK-based charity The Donkey Sanctuary said "the ejiao industry drives a massive global trade in donkey skins, much of it illegal." It said around 5.9 million donkeys were killed worldwide last year.
The ejiao trade is expected to require at least 6.8 million donkey skins by 2027.
The rising value of donkeys means they have increasingly become targets for criminals.
A man rides a donkey-pulled cart carrying corn husks along the banks of the Rio Bravo after heavy rains, in Ciudad Juarez, Mexico. Reuters
"Traders exploit vulnerable people using large and sophisticated networks of agents to pressure donkey owners into selling their animals," the charity said.
"Illegal networks operate across the continent, often without consequence, stealing and slaughtering donkeys in the night," it added.
"Donkeys die in often unregulated, inhumane, and unsanitary conditions, and large numbers perish on their way to slaughterhouses," it continued.
The impact on humans is particularly felt by women and children, who rely on donkeys for farming activities such as ploughing and for carrying goods to market.
The criminal operations also generated health risks, The Donkey Sanctuary said.
"The transportation of untreated skins and improper disposal of donkey carcasses risk triggering the spread of infectious diseases and damaging local ecosystems."
Agence France-Presse
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
2 days ago
- Zawya
Guizhou's Fruitful Eco-Construction: from 'Experimental Zone' to 'Pilot Zone'
GUIYANG, CHINA - Media OutReach Newswire - 27 June 2025 - Eco Forum Global Guyang 2025 will be held in Guiyang, Guizhou from July 5th to 6th. Guizhou, located in the southwest of China, is using an ecological pen to paint a gorgeous green picture along her mountains and rivers. From an 'Experimental Zone' to a 'Pilot Zone', Guizhou has embarked on a new path of green development characterized with prosperous economy, wealthy people and ecological beauty. Significant Improvement in Eco-environment Guizhou persists in winning the 'Five Major Battles' of pollution prevention and control and coordinates the integrated eco-restoration of mountains, rivers, lakes, farmland, forests, grasslands and deserts. By 2024, the ambient air quality in 9 key cities and 88 counties in Guizhou has met Grade II, and the overall surface water quality has been remarkable. The excellent water quality rate of 222 monitoring sections of major rivers is 99.1%, and that of 23 exit sections reaches 100%. The water quality compliance rate of centralized drinking water sources at or above the county level remains 100%. The Wushui River (Wuyang River) in Qiandongnan Miao and Dong Autonomous Prefecture has been successfully selected as one of the Outstanding Cases of Beautiful Rivers and Lakes in China. Since 2019, the water quality in Qiandongnan Prefecture has been among the top 10 in China for six consecutive years. Mr. Wu Hougui, a member of the Loong Boat Team in Ximen Community, Zhenyuan County, said, 'The Loong Boat Competition tradition can not be inherited for thousands of years without lucid waters and lush mountains.' Flourishing Green Industries Guizhou is accelerating the transformation and upgrading of traditional industries, integrating green and low-carbon concept throughout the entire process of high-quality development. Guizhou has successfully established 85 national level green factories and 22 green industrial parks. The green economy accounts for about 48%. The first commercial hydrogen locomotive in China has started trial operation on Guizhou Meijin Railway Special Line in Zhongshan District, Liupanshui City, opening up a new path for clean coal transportation. The construction of 'Electric Guizhou' has achieved fruitful results. Since the beginning of 2025, a total of 3,054 electric heavy-duty trucks have been promoted and applied in the energy sector, reducing carbon dioxide emissions by about 332,000 tons. The forestry has also achieved a huge leap forward. In 2014, the total output value of Guizhou's forestry was only 60.1 billion yuan, and it exceeded 465.4 billion yuan in 2024. Over the past decade, the forest coverage rate has increased from 49% to 63.3%, with a forest area of 166 million mu. Innovative Eco-protection System In 2024, Guizhou took the lead in establishing a unified and standardized mechanism for issuing forestry carbon tickets at the provincial level in China, granting the first batch of 10 provincial forestry carbon tickets and achieving a total of 11 million yuan in transactions. In addition, a total of 120 water rights transactions have been completed, with a transaction volume of 86.0287 million cubic meters, amounting to 31.5387 million yuan. Public Participation in Eco-construction Guizhou's tradition of 'Tree Planting for New Year Celebrations' has continued for 11 years, with 605 million more seedlings newly planted here. Since the 14 th Five-Year-Plan, Guizhou has shifted its greening focus from 'coverage expansion' to 'quality improvement'. Through projects such as degraded forest restoration and forest nurturing, the forest has been both 'greened' and 'increased in value'. Meanwhile, with both 'civil defense and technical defense', Guizhou has successfully protected the ecological foundation. For instance, there are 87 remote video surveillance points established in Guiyang to prevent forest fire. There are 400 infrared cameras installed to track the rare species in Mount Fanjing and more than 40,000 forest chiefs ready to guard forest resources. Efficient Resource Utilization and Green Transformation Guizhou has implemented the strategy of 'Refined Development of Rich Minerals' to promote efficient utilization of resources. In the field of phosphorus chemical industry, Qiannan Prefecture has laid out modern chemical and new energy battery material industries, realizing the transformation of phosphorus from 'fertilizer' to 'material'. The total output value of phosphorus based modern chemical and new energy battery materials has exceeded 50 billion yuan. Furthermore, in the field of aluminum industry, Shuicheng Economic Development Zone has achieved 100% in-situ conversion of aluminum liquid, and the number of aluminum related enterprises has increased from 1 in 2016 to 54. Guizhou is also actively developing the cultural tourism industry and digital economy. The Zhenyuan Loong Boat Race Cultural Festival has unleashed the consumption potential of cultural tourism. During the Loong Boat Festival this year, Zhenyuan County received 253,900 tourists, realizing a total tourism revenue of 234 million yuan. Additionally, Guizhou's digital economy growth rate has been among the top in the country for 9 consecutive years. There are 48 national key data centers under construction and in operation, making Guizhou one of the regions with the most intelligent computing resources and the strongest capabilities in China. Hashtag: #Guizhou The issuer is solely responsible for the content of this announcement. Guizhou Environmental Protection Industry Association
Zawya
2 days ago
- Zawya
Stung by high prices, Americans make their own weight-loss drugs
In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the U.S. Food and Drug Administration. One comes mixed with tirzepatide, the active ingredient in Eli Lilly's Zepbound. Spencer, 50, is not part of any drug trial but mixes the cocktails herself, using tiny doses that she believes are safe. The total cost is about $50 monthly, as little as one-tenth of what she would expect to pay their makers for full treatment. The drugs – glucagon-like peptide-1 (GLP-1) weight-loss medicines – are manufactured and shipped from China, according to the packaging. She orders them through online vendors. Spencer belongs to a fast-growing group of Americans turning to what many call the "gray market" for obesity medicines, bringing cheap active ingredients from China often labeled as for research purposes, according to import data and social media postings. It's a trend that drugmakers Lilly and Novo Nordisk, which makes Wegovy, say is dangerous as well as illicit. Reuters tracked online forums and interviewed seven people who said they bought obesity medicines through this market, including an attorney in Arizona who works for a state insurance agency, a retired nurse in Illinois and a Type 1 diabetic in Louisiana, who said the medicine helped cut her insulin intake by more than half. For more than a year there has been demand for cheap Chinese-made powders, exacerbated by limited health insurance coverage in the U.S. Buyers told Reuters the gray market received a boost from an FDA ruling last year that U.S. compounding pharmacies – outsourcing facilities that create drugs in shortage – must stop selling obesity medicines more cheaply than the companies that developed them. Shipments of such active ingredients from Chinese entities not registered with the FDA jumped by 44% in January from the previous month, according to research by the Partnership for Safe Medicines, a public health group focused on the safety of prescription drugs. It said its findings are likely an undercount, because unregistered vendors may not disclose that their parcels contain medicines. Packages valued at less than $800 that enter the U.S. under the de minimis rule are not included in the data. Nearly three-quarters of U.S. adults are overweight or obese, according to government estimates, but a survey by nonprofit health policy research organization KFF found only about 8% say they have taken medicine for weight loss. Most of the gray market buyers Reuters interviewed had told their medical providers they were taking GLP-1 medicines but not where or how they bought them. Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to consulting firm Mercer. Many Americans have paid out of pocket for cheaper compounded drugs. Interest in taking small doses of the drugs has also spurred the online marketplace, buyers said. Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny. They swap advice for navigating the market, exchanging information on vendors, shipping and dosage, and sometimes clubbing together to cover the cost of testing the powders. One forum is called StairwayToGray. It has more than 21,000 members on Telegram and recently was gaining nearly 1,000 members weekly. It did not respond to Reuters' inquiries, and blocked access to the forum after receiving them. It has a website where it says it does not facilitate group purchases. "This community is filling the gaps and being our own regulators, ensuring testing and access for everyone who needs it. Because you shouldn't have to choose between your health or your wallet," it says. Spencer stores her stocks in her fridge and makes them up in the kitchen – carefully measuring sterile water, rolling the vial between her fingers until the powder dissolves, and drawing the liquid into a syringe before injecting it into her thigh or belly. She has lost 24 pounds. "This is working so well for me. It's so easy. It's cheap," said Spencer, who assumes her health plan wouldn't cover the drugs. "I don't know what I would do without this medicine." "VERY DANGEROUS" In February, 38 U.S. state and territory attorney generals wrote the FDA seeking action against illegally sold weight-loss medicines, including "research purposes only" ingredients from China. "Much like with counterfeit versions, these active ingredients come from unregulated, undisclosed sources ... and pose risks of contamination and inclusion of foreign substances," they said. Shabbir Safdar, executive director of the Partnership for Safe Medicines, said unapproved drugs can have problems with sterility, purity and consistency. "It can be very dangerous. You're playing the role of your own doctor, pharmacist, and FDA inspector," he said. Of those interviewed, only Spencer reported any problems: She once got her math wrong and overdosed, resulting in several days of severe flu-like symptoms. Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working with social media companies to identify and remove posts that promote unsafe products, including those described as "research use only." "We will continue to take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same," a Lilly spokesperson told Reuters. Novo Nordisk also said it continues to take action against entities that violate laws and regulations and put patient safety at risk. America's Poison Control agency, which maintains the nation's poison data surveillance system and monitors GLP-1 exposures, said it could not reliably track cases involving unregulated "research chemical powders" because they are sold under various names and formulations. The FDA's goal is to stop illegal sales of pharmaceutical medicines at the border, said George Karavetsos, former director of the FDA's Office of Criminal Investigations and co-author of the imports study. But understanding the true nature and intended use of small parcels arriving from China can be difficult, and the FDA rarely seeks charges against consumers for personal use, he said. The FDA said it urges consumers to buy from licensed pharmacies and "avoid products of unknown quality," adding it was actively protecting consumers by intercepting illegal products at ports, and warning companies that market unapproved weight-loss medicines, including those mislabeled as "for research purposes." Although the forums show suppliers purportedly in China, Reuters was not able to verify where the drugs originate. None of the vendors responded to requests for comment. A Reddit spokesperson said the site prohibits facilitating transactions involving drugs and it had shut down a group found to be doing this. Telegram said it removes "more than a million" instances of harmful content each day, but did not comment directly. MICRODOSE MISTAKE Spencer has polycystic ovary syndrome and for years struggled with weight gain and hypertension. She decided to try obesity medicines after seeing claims on social media that microdosing them could give fewer side effects, and bought semaglutide, the active ingredient in Wegovy, from a compounding pharmacy for about $200 per month. She started on one-fifth of the lowest dose. Within days, intermittent joint pain she often suffered had dissipated: "I didn't realize how badly I hurt until the pain was gone." The cost would reach about $500 a month if she bought the drug from Novo, which recently introduced one-off discounts. After a week, Spencer said, her blood pressure dropped so low she thought she might pass out, so she stopped taking hypertension medicine. Her pressure stabilized and she lost three pounds. She wanted to understand more about microdosing, and turned to the gray market last summer. On Reddit, users told how another Novo drug in development, called CagriSema, had helped reduce inflammation and hunger pangs better than semaglutide. CagriSema is Novo's next-generation obesity drug candidate, still in clinical trials so not available to the public. It combines semaglutide with another molecule, called cagrilintide, which intensifies the hormone-mimicking effects to regulate blood sugar and reduce hunger. Spencer was intrigued. She found a U.S. reseller saying they tested Chinese-made CagriSema through a third-party lab before selling it to Americans. On microdoses of CagriSema, Spencer could enjoy food in small quantities. "I could say 'yes' because I knew I was only going to eat four bites." In October, Spencer saw on Reddit that tirzepatide might also reduce inflammation. She placed a new order for vials that contained cagrilintide and tirzepatide combined, dubbed "cagri-tirz." Now each Monday, Spencer injects herself with tiny amounts of cagri-tirz. On Thursdays, she uses retatrutide, a new obesity medicine by Lilly, also in trials. As she was switching to cagri-tirz, Spencer made a dangerous mistake. She calculated her new dosage without realizing the concentration of cagrilintide in the combined vials was 10 times higher than she had taken previously. "I was an idiot. I didn't do my math. Or rather, I did the math for the tirzepatide but not for the cagri," she said. Almost immediately, she began vomiting. The reaction was so severe she had trouble moving. She forced herself to drink water but couldn't eat. After four days, when symptoms lifted, she had lost seven pounds. Despite the blunder, Spencer didn't consider returning to compounded versions of the drugs or abandoning them altogether. She is not regularly monitored by a healthcare provider, but says her treatment has led to a "life-changing" reduction in weight, joint pain and blood pressure. "HONOR SYSTEM" Gray-market buyer Marie, 41, shows how do-it-yourself drugmakers are organizing. She describes herself as a "soccer mom" from the Midwest and asked to be identified by her middle name to protect her privacy. Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs. She began to worry about her supply. Browsing on Reddit, she discovered links to Telegram and a trove of detailed instructions from experienced users for buying weight-loss drug ingredients from China. Customers said they often paid with Bitcoin or through mobile payment service Venmo. After a month closely following the forums, Marie made a purchase in January. The package that arrived contained 20 small glass vials of white powder with red caps. There were no instructions. The vendor who advertised the package on Telegram said it came from China. Marie returned to the forums and joined a group of 52 other customers who paid a total of $1,020 to a Tennessee-based company called Peptide Test. Six members mailed in a vial each and the others chipped in their share of the fee. The lab found the samples were pure. Peptide Test declined to comment. "It's an honor system," said Marie. "These groups are very supportive in a way I haven't seen on the internet before." Before her first injection, Marie gave her husband details of what she had done. They agreed that if needed, he would disclose everything to the emergency medics. But she was fine. In March, Marie volunteered to organize testing a new order of tirzepatide. The group formed on Telegram after users received vials from the same vendor which they judged to be from the same batch based on the color of the caps. In all, 38 buyers agreed to chip in for the $1,300 bill, and decided by poll that five vials would be enough. Five people sent drugs to the lab, Janoshik Analytical in the Czech Republic, which found the vials contained tirzepatide, as purported, with purity between 99.78% and 99.85%. Janoshik's CEO, Peter Magic, is a former amateur weight-lifter. He said his company started out more than a decade ago testing performance-enhancing drugs for online buyers. Last year, it tested 3,050 samples of obesity drugs, up from just over 650 samples in 2023. "We're testing hundreds of these every week," said Magic, whose company helps customers navigate customs requirements for shipping chemicals. (Reporting by Robin Respaut in San Francisco and Maggie Fick in London; additional reporting by Patrick Wingrove in New York; edited by Sara Ledwith and Michele Gershberg)
Arabian Post
2 days ago
- Arabian Post
Tanoto Foundation Backs Landmark Research to Unlock the Code of Asian Prevalent Diseases
Understanding Asian Cancers and Diabetes Through an Asian Lens SINGAPORE – Media OutReach Newswire – 27 June 2025 – Tanoto Foundation today announced the funding of two transformative, Singapore-based medical research projects focused on diseases that disproportionately affect Asian populations: prevalent and aggressive cancers, and young-onset Type 2 diabetes. The multi-year initiatives aim to generate data-driven insights that can accelerate diagnosis, improve patient outcomes, and guide public health policy. NCCS and SGH secure research funding from Tanoto Foundation for projects tackling Asian-prevalent cancers and young-onset diabetes to drive breakthroughs in regional health Despite global strides in medicine, Asia continues to face rising rates of cancer and diabetes – diseases that are biologically and clinically distinct in Asian populations but remain under-researched due to a lack of region-specific data. The two research projects, from National Cancer Centre Singapore and Singapore General Hospital, will focus on filling these gaps through deep genomic studies and innovative risk-prediction models. ADVERTISEMENT Imelda Tanoto, Member of the Board of Trustees, Tanoto Foundation said: 'Singapore is well-positioned to lead in medical science. It has strong research institutions and a population that reflects the diversity of Asia. By supporting researchers here who are focused on health issues that affect Asians, we hope to help drive discoveries that make a real difference to people's lives — both in Singapore and across the region.' Tackling Asian-Prevalent Cancers Led by Dr Jason Chan, Medical Oncologist, National Cancer Centre Singapore, the research will investigate four types of cancers with high prevalence and poor outcomes in Asia: Breast Cancer in Asian Women, marked by earlier onset and biological differences compared to Western populations T/NK-Cell Lymphomas, an aggressive blood cancer dominant in East Asians with limited treatment options Bile Duct Cancer (Cholangiocarcinoma), increasingly linked to environmental exposures specific to Asia Rare Asian Cancers, collectively neglected but accounting for up to 25% of all cases in the region These cancers are devastating but remain poorly understood because most research has focused on Western populations,' said Dr Chan. 'By decoding their molecular and genomic landscapes in Asian patients, we want to uncover new diagnostic and therapeutic opportunities to benefit patients.' A key feature of the project is its open-access commitment: anonymised data will be freely available to the broader research community to accelerate further discovery and collaboration. Unmasking Diabetes Risk in Young Singaporeans The second research project, led by Dr Daphne Gardner, Endocrinologist, Singapore General Hospital, will address the rising incidence of Type 2 diabetes in young adults, particularly prevalent in Singapore, where 1 in 5 young adults have prediabetes or diabetes, despite being of normal weight. ADVERTISEMENT Unlike traditional assessments that rely heavily on BMI and family history, this project will develop a next-generation risk prediction tool by incorporating non-traditional indicators such as body fat distribution, continuous glucose monitoring, and health-seeking behaviour. 'Many young Asians with diabetes don't fit the usual risk profile. They're lean, active, and often overlooked by current screening models,' said Dr Gardner. 'We want to change that by identifying new risk signals and developing tools that are tailored to Singapore's population and beyond.' Findings from the study aim to inform national diabetes screening guidelines and lead to earlier interventions that can curb long-term complications. Singapore as a Hub for Medical Research Advancement In addition to previously supported research projects, these two initiatives reflect a growing recognition of Singapore's role in advancing precision medicine for Asian populations, driven by strong clinical infrastructure, genomic capabilities, and public-private partnerships. Imelda Tanoto added: 'We believe precision health can change how we treat and prevent diseases. We're supporting researchers who are not only breaking new ground, but also making sure their work reaches people and communities across Asia. This is something deeply personal to us — it's about improving lives in a way that's inclusive, meaningful, and lasting.' This announcement marks a key milestone in Tanoto Foundation's continuing effort to improve the quality of healthcare and health standards, leading to longer and better healthspans. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement. About Tanoto Foundation At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes. More information is available at
